This project aims to investigate the safety amd tolerability of oral dosage HAMSAB. HAMSAB was delivered orally, daily for 6 weeks to adult subjects with well managed and longstanding T1D. Stool samples were collected at baseline prior to adminstering HAMSAB, at 6 weeks after dosage and at 12 weeks, after a six week washout period.